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Abstract
Objective: To determine if transfusing ABO compatible platelets has a greater effect on 
incremental change in platelet count as compared to ABO incompatible platelets in critically ill 
children.
Design: Secondary analysis of a prospective, observational study. Transfusions were classified as 
either ABO compatible, major incompatibility or minor incompatibility. The primary outcome was 
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the incremental change in platelet count. Transfusion reactions were analyzed as a secondary 
outcome.
Setting: Eighty two pediatric intensive care units in 16 countries.
Patients: Children (3 days to 16 years of age) were enrolled if they received a platelet transfusion 
during one of the predefined screening weeks.
Interventions: None
Measurements and Main Results: Five hundred and three children were enrolled and had 
complete ABO information for both donor and recipient, as well as laboratory data. 342 (68%) 
received ABO-identical platelets, 133 (26%) received platelets with major incompatibility, and 28 
(6%) received platelets with minor incompatibility. Age, weight, proportion with mechanical 
ventilation or underlying oncologic diagnosis did not differ between the groups. After adjustment 
for transfusion dose, there was no difference in the incremental change in platelet count between 
the groups; the median (IQR) change for ABO-identical transfusions was 28 (8–68) x109 cells/L, 
for transfusions with major incompatibility 26 (7–74) x109 cells/L, and for transfusions with 
minor incompatibility 54 (14–81) x109 cells/L (p = 0.37). No differences in count increment 
between the groups were noted for bleeding (p=0.92) and non-bleeding patients (p=0.29). There 
were also no differences observed between the groups for any transfusion reaction (p=0.07).
Conclusions: No differences were seen in the incremental change in platelet count nor in 
transfusion reactions when comparing major ABO incompatible platelet transfusions with ABO 
compatible transfusions in a large study of critically ill children. Studies in larger, prospectively 
enrolled cohorts should be performed to validate whether ABO matching for platelet transfusions 
in critically ill children is necessary.
Keywords
platelet transfusion; ABO compatibility; critical illness; pediatrics
INTRODUCTION
Platelet transfusions are frequently prescribed for critically ill children who are either 
bleeding (therapeutic transfusions) or at risk of bleeding (prophylactic transfusions). A 
recent large, international, observational study of both therapeutic and prophylactic 
transfusions in critically ill children demonstrated a high mortality rate (25%) for all 
children receiving a platelet transfusion for any indication, as well as an independent 
association between total platelet dose and mortality.1 In children receiving platelet 
transfusions, each additional dose 10 mL/kg of platelets received was associated with a 2% 
increase in mortality, after accounting for severity of illness represented by organ 
dysfunction scoring on the day of transfusion, bleeding and the use of extracorporeal life 
support. Any modifiable determinants of platelet transfusions should therefore be explored 
given the potential morbidity and mortality that may be associated with this therapy.
Providing ABO-identical platelet transfusions is not always considered necessary. The 
requirement for matching ABO blood group for platelets are not as stringent as those for 
RBC transfusions. Platelets express ABO blood group antigens2 and correspondingly the 
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plasma found in platelet products may contain antibodies against A or B antigens, depending 
upon the ABO type of the donor, that may be reactive with the recipient’s antigens.3 The 
practice of ABO matching of platelet transfusions in blood banks is variable with no 
consensus guidelines; approximately 20% of hospitals have no institutional written 
guidelines on this topic.4 The proportion of critically ill children receiving ABO compatible 
platelet transfusions has not been reported. The transfusion of ABO incompatible platelets 
may have the benefit of effectively increasing the availability of platelet product options, 
which is considered a limited resource, especially in emergencies such as life-threatening 
hemorrhage. Increased availability also reduces waste of platelet products, given their short 
storage duration (5–7 days). However, ABO mismatching has been implicated in acute 
hemolysis5, increased fever and alloimmunization6, and reduced efficacy of platelet 
transfusions.7
Few studies have demonstrated the effects of ABO incompatibility in pediatric platelet 
transfusions8 and no previous studies have reported the results in critically ill children. 
Therefore, as the primary objective of this study, we sought to describe the efficacy of ABO 
compatibility on the incremental change in platelet count following platelet transfusions in 
critically ill pediatric patients. As a secondary objective, we evaluated associations between 
the receipt of ABO incompatible platelet transfusions and the occurrence of transfusion 
reactions. Lastly, we evaluated patient variables associated with the receipt of compatible 
versus incompatible platelet transfusions.
METHODS
This study, approved by the Institutional Review Board at Weill Cornell Medicine, is an a 
priori secondary analysis of a prospective, observational study examining the epidemiology 
of platelet transfusions in critically ill children (“Point Prevalence Study of Platelet 
Transfusions in Critically Ill Children,” otherwise known as P3T).1 Eighty-two sites from 
sixteen countries contributed data. Each site was assigned six random weeks (between 
September 2016 to April 2017) during which they screened subjects for eligibility and 
enrollment. A child was enrolled if he/she was between the ages of 3 days and 16 years of 
age and received a platelet transfusion prescribed by the intensive care medical team during 
one of the screening days. Patients were excluded if life expectancy was considered to be 
less than 24 hours, gestational age of the patient was less than 37 weeks at the time of 
admission, or the patient had already been enrolled in a previous screening week. In 
addition, they were excluded from this analysis if they received multiple pooled platelet 
units with different ABO compatibility or if they received several platelet transfusions in the 
interval between laboratory assessments. In total, 16,934 patients were screened and 559 
eligible patients receiving platelet transfusions were enrolled. Data for the P3T study were 
recorded in the Research Electronic Data Capture (REDCap) web data application and 
extracted for this secondary analysis. Data regarding ABO compatibility was collected 
around the platelet transfusion at time of enrollment but did not include all data from every 
platelet transfusion received during the subject’s PICU stay.
Data collected included patient demographics, reason for admission, any prior platelet 
transfusions during the current ICU admission, validated measures of organ dysfunction 
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(PELOD-2 scoring)9, information regarding the platelet product (including the ABO type of 
the donor and recipient), and any adverse reactions that occurred during the transfusion. The 
adverse reactions documented included fever of ≥ 38.5C (or increase in temperature by 1 
degree Celsius from baseline in a patient who was already febrile), hypotension, 
bronchospasm, urticaria, and hemolytic reactions. The total platelet count before and after 
the platelet transfusion was recorded if obtained as standard of care. The timing of the 
assays was determined by the medical team. The pre-transfusion platelet count was assayed 
within 36 hours of start of the transfusion and recorded according to the following time 
intervals: < 1 hour, 1–2 hours, 2–6 hours, 6–12 hours, 12–24 hours and 24–36 hours. The 
timing of the post-transfusion platelet count was recorded in relation to the completion of 
the transfusion of interest with the same time intervals as listed above.
ABO major incompatibility was defined as platelets from A, B or AB donors to O recipients, 
or from AB donors to A or B recipients. Transfusions with bidirectional incompatibility (A 
donor to B recipient or B donor to A recipient) were included in the major incompatibility 
group. Minor incompatibility was defined as platelets from O donors to A, B or AB 
recipients, or from A or B donors to AB recipients.
Demographic and clinical characteristics were described as counts and percentages or 
median and interquartile range (IQR) as appropriate. Categorical variables were compared 
using either Chi-squared or Fisher’s exact test, depending on the size of the sample. 
Continuous variables were compared using Kruskal Wallis test. Two-sided p values below 
0.05 were considered significant and there was no adjustment made for multiple 
comparisons. If the Kruskal Wallis test showed a statistical difference between groups, then 
one to one comparison was performed to determine which groups were significantly 
different. All analyses were conducted using SPSS version 25 (IBM Corp, Armonk, NY).
RESULTS
Of the 559 subjects enrolled in P3T, five hundred and three (90%) had data on ABO 
compatibility and pre and post-transfusion platelet counts recorded. Of these, 342/503 (68%) 
were classified as ABO compatible, 133/503 (26%) had major incompatibility and 28/503 
(6%) had minor incompatibility. Seven transfusions had bi-directional incompatibility and 
were classified along with the major incompatibility group.
The transfusions occurred across diverse locations: 351/503 (70%) in North America, 
81/503 (16%) in Europe, 35/503 (7%) in Oceania, 21/503 (4%) in Asia, and 15/503 (3%) in 
the Middle East. There was variability in the percentage of compatible transfusions given in 
each region: 66% in North America, 70% in Europe, 71% in Oceania, 91% in Asia, and 67% 
in the Middle East (p< 0.001).
The demographics and clinical characteristics are described in Table 1. The groups were 
comparable across various characteristics except for median PELOD-2 scoring being 
slightly higher in the ABO minor incompatibility group as compared to ABO-identical 
transfusions or major incompatibility groups (p=0.04). For patients weighing less than 15kg, 
161 (67%) received ABO compatible transfusions, 65 (27%) received transfusions with 
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major incompatibility and 15 (6%) received transfusions with minor incompatibility. The 
admitting diagnoses of the subjects and the therapies they received are summarized in Table 
2. There were no differences in admitting diagnoses (apart from those with septic shock and 
those with cardiac insufficiency not related to cardiac surgery), medications with antiplatelet 
effects, use of extracorporeal therapies, or median dose of platelet transfusions prior to 
enrollment in the study between the three groups. Patients received a median (IQR) platelet 
dose of 30 (13–86) mL/kg during their PICU admission prior to enrollment in the study. The 
total median (IQR) number of platelet transfusions received during their entire admission 
was 4 (2–11).
Table 3 describes the receipt of the three ABO compatibility for bleeding versus non-
bleeding indications. The indication for the platelet transfusions (treatment of bleeding 
versus prophylaxis) differed between the three ABO compatibility groups (p=0.04). Thirty-
two percent (110/342) of the ABO compatible transfusions were given to bleeding patients. 
Forty-two percent (56/133) of the transfusions with major incompatibility were given to 
bleeding patients and twenty-one percent (6/28) of the transfusions with minor 
incompatibility were given to bleeding patients. Table 4 illustrates the attributes of the 
platelet products transfused.
The breakdown of time intervals between the pre-transfusion platelet count and the start of 
the transfusion of interest are as follows (data was available for 501 transfusions): 36/501 
(7%) within < 1 hour, 102/501 (20%) within 1–2 hours, 223/501 (44%) within 2–6 hours, 
105/501 (21%) within 6–12 hours, 29/501 (6%) within 12–24 hours and 6/501 (<2%) within 
24–36 hours. The breakdown of time intervals between the end of the transfusion of interest 
and the post-transfusion platelet count are as follows (data on timing is available in all of the 
transfusions): 43/503 (9%) within < 1 hour, 81/503 (16%) within 1–2 hours, 171/503 (34%) 
within 2–6 hours, 124/503 (25%) within 6–12 hours, 67/503 (13%) within 12–24 hours and 
17/503 (<4%) within 24–36 hours. There was a wide variation in the interval changes in 
platelet count, corrected for a standard dose of 10 mL/kg, with the majority of interval 
changes occurring between −40 to +150 ×109 cells/L. For all transfusions, there was a 
median (IQR) interval rise of 28 (8–70) x109 cells/L for every 10 mL/kg transfused. Figure 1 
shows the interval change for each ABO compatibility group. These results were consistent 
when bleeding and non-bleeding patients were analyzed separately. In bleeding patients, the 
median (IQR) interval rise was 29 (8–64) x109 cells/L for every 10 mL/kg transfused for 
ABO compatible transfusions, 23 (7–105) x109 cells/L for transfusions with major 
incompatibility, and 35 (4–108) x109 cells/L for transfusions with minor incompatibility 
(p=0.93). Similarly, for non-bleeding patients, the median (IQR) interval rise was 27 (8–70) 
x109 cells/L for every 10 mL/kg transfused for ABO compatible transfusions, 26 (8–55) 
x109 cells/L for transfusions with major incompatibility, and 57 (17–78) x109 cells/L for 
transfusions with minor incompatibility (p=0.29). Figure 2 demonstrates the interval 
changes in total platelet count in bleeding versus non-bleeding subjects by ABO 
compatibility group.
Given the possibility that the presence of extracorporeal support may bias the results since it 
is known to affect the incremental change in platelet count due to adherence or destruction, a 
subgroup analysis was performed excluding those patients on ECLS. The results were 
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consistent. The median (IQR) interval rise was 28 (8–65) x109 cells/L for every 10 mL/kg 
transfused for ABO compatible transfusions, 22 (7–74) x109 cells/L for transfusions with 
major incompatibility, and 37 (4–78) x109 cells/L for transfusions with minor 
incompatibility (p=0.74).
Similarly, given the fact that subjects with an underlying oncologic diagnosis would have 
likely been exposed to more platelet transfusions and therefore have a less robust response in 
the incremental change in platelet count, we performed a subgroup analysis of the 295 
subjects who did not have an underlying oncologic diagnosis. The results remained 
consistent. The median (IQR) interval rise was 36 (10–79) x109 cells/L for every 10 mL/kg 
transfused for ABO compatible transfusions, 34 (8–90) x109 cells/L for transfusions with 
major incompatibility, and 57 (37–81) x109 cells/L for transfusions with minor 
incompatibility (p=0.39).
Given the possibility of differences in those multiply transfused, a sub-group analysis was 
performed in the 92 subjects who had received ≥ 30 mL/kg of platelet transfusions during 
their admission, prior to enrollment in the study. In this group, 61/92 (66%) received ABO 
compatible transfusions, 27/92 (29%) received transfusions with major incompatibility, and 
4/92 (5%) received transfusions with minor incompatibility. The median (IQR) interval rise 
in platelet count for every 10 mL/kg of platelets transfused for each group was as follows: 25 
(9–68) x109 cells/L for ABO compatible transfusions, 28 (6–51) x109 cells/L for 
transfusions with major incompatibility and 61 (46–80) x109 cells/L for transfusions with 
minor incompatibility. There were no statistically significance differences between these 
median values (p=0.11).
Data on transfusion reactions were available in 493 subjects. Table 5 depicts the incidence of 
transfusion reactions. There was no significant difference in any transfusion reaction 
between the groups (p=0.07) or in any individual adverse event. There were no hemolytic 
reactions or septic reactions documented during any of the transfusions.
DISCUSSION
This study reports the count increment of platelet transfusions as it relates to ABO 
compatibility in the largest cohort of critically ill children published to date. It is the first 
study to report on the proportion of ABO compatible versus incompatible platelet 
transfusion received and the regional variability in practice. More than two-thirds of children 
received ABO-identical platelet transfusions. Though there were minor differences between 
the ABO compatibility groups regarding admitting diagnosis, the population represents a 
diverse cohort both in geography and pathophysiology. No patient characteristics were 
associated with the receipt of an ABO compatible platelet transfusion. No differences were 
seen in the incremental differences in platelet count following transfusion, between the 
compatibility groups. Likewise, no differences were seen in documented transfusion 
reactions, in any of the groups.
Our results should be interpreted in the context of ongoing uncertainty and controversy 
regarding reduced efficacy following the transfusion of ABO incompatible platelets. 10,11 
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Several adult studies have reported a benefit to providing ABO compatible platelet 
transfusions. Increased post-transfusion platelet count increments have been reported in 
platelet survival studies in both healthy subjects12 and adult hematology patients13–15 for 
those who received ABO compatible as compared to platelet transfusions with major 
incompatibility. Randomized controlled trials have demonstrated that the differential 
increments in platelet count post transfusion are most pronounced in patients who have 
received multiple doses of platelets (generally defined as > 3 separate transfusions).16 One 
hypothesis relates this to the development of high titer isoagglutinins, antibodies to human 
leukocyte antigens (HLA) or antibodies to human platelet antigens (HPA).17 One study of 
six platelet refractory patients reported that these patients who received ABO incompatible 
platelets have circulating immune complexes of ABO antigens and their corresponding 
antibodies for at least several days.18 Circulating ABO immune complexes have been shown 
to affect platelet function, red cell integrity and hemostasis in vitro.19 Unfortunately, there 
was no control group in this study to determine if ABO immune complexes also occur in 
patients who do not have platelet refractoriness. No studies have been reported in critically 
ill adults.
In comparison to these studies in adults, we did not detect significant differences in post-
transfusion platelet count increments when comparing ABO compatible platelet transfusions 
to those with major or minor compatibility in critically ill children. There are very limited 
published reports on the efficacy of ABO compatibility for platelet transfusions in children. 
One study on this topic was published by Julmy and colleagues in 2009 and focused on fifty 
children with hematologic malignancies, solid tumors or aplastic anemia who were receiving 
platelet transfusions (primarily for prophylactic indications) and who were prospectively 
enrolled.19 The primary comparison was the post-transfusion platelet count (measured one 
hour after completion of the transfusion) between ABO-identical and major-mismatched 
groups. After comparing the laboratory results of 400 transfusions, the authors reported 
significantly worse efficacy of ABO major-mismatched transfusions as compared to 
matched transfusions. There was no analysis of clinical outcomes included in the study.
In comparison to the previously reported results in children, we did not detect significant 
differences in post-transfusion platelet count increments when comparing ABO compatible 
platelet transfusions to those with major or minor compatibility. Our subjects had generally 
been multiply transfused and our subgroup analysis showed no differences in platelet 
increment after transfusion for those who had received ≥ 30 mL/kg of platelet transfusions 
during their admission, prior to enrollment. In addition, in contrast to most other published 
studies, our population was quite diverse geographically and reports on regional differences. 
Since no accepted standard for ABO matching of platelet transfusions exists, practice varies 
significantly. In some European countries, the titers of antibodies to the A and B antigens are 
routinely measured in platelet units and then labeled as “high titer negative.”20 This allows 
for selection of these units specifically when incompatible platelets are transfused, thus 
theoretically minimizing the negative consequences. Similarly, there are regional differences 
in product preparation; for example, some platelet products are suspended in additive 
solution versus plasma.4 These variations may also affect the incremental changes in platelet 
counts observed.
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Despite differences seen in platelet counts following transfusion of the ABO compatible 
versus ABO incompatible products, many argue that there is little evidence of differences in 
clinical outcomes shown in adults receiving platelet transfusions.9,10 A recently published 
systematic review evaluating both randomized controlled trials and observational studies 
regarding ABO incompatibility of platelet transfusions concluded that the clinical benefit of 
ABO matching was unclear since there is inconclusive data.21 Similarly, in a retrospective 
examination of the platelet transfusions administered during the Platelet Dose (PLADO) 
study, ABO matching was not predictive of the time to bleeding, if bleeding was to occur.22 
We did not detect any differences in the rates of transfusion reactions between compatibility 
groups. An association between ABO compatibility and bleeding was not possible since our 
study did not include bleeding scores due to the lack of consensus regarding their value in 
children and the difficulty in obtaining these scores in an unfunded international study.
This study reports on ABO compatibility of platelet transfusions in the largest cohort of 
children to date. The analysis is the first to report the proportion of ABO compatible 
transfusions received in critically ill children. Additional strengths of our study relate to the 
population which represents a diverse cohort both in geography and pathophysiology. More 
than two-thirds of children received ABO-identical platelet transfusions. No patient 
characteristics were associated with the receipt of an ABO compatible platelet transfusion.
However, some limitations to our study exist. Although we reported on differences in the 
rates of transfusion reactions between compatibility groups, we did not assess for bleeding. 
Due to the inherent design of a point prevalence study, compatibility data was collected 
around one platelet transfusion and not around every platelet transfusion received by each 
enrolled subject during his/her admission; it is therefore unknown whether subjects received 
all ABO compatible versus a combination of compatible and incompatible transfusions. 
Some evidence suggests that ABO incompatible transfusions can affect the incremental 
platelet change following subsequent transfusions.23 As an observational study, post-
transfusion platelet counts were assessed at the medical team’s discretion and thus not 
limited to a one hour post-transfusion assessment. We did not collect information on the 
variation of platelet count analyzers that was likely present between the hospitals. 
Additionally, each platelet transfusion contains a different number of platelets and we did 
not collect information on the number of platelets in each transfused aliquot. We also did not 
collect information on the ABO titer status of units transfused in Europe. We did not collect 
information on hemolysis (apart from acute hemolytic reactions during that transfusions) 
which may have occurred following the transfusion. Splenomegaly, an important clinical 
characteristic that can affect the post transfusion platelet counts, was not recorded.
CONCLUSIONS
In this large observational study in critically ill children, no differences were seen in 
incremental platelet count or transfusion reactions following the transfusion of ABO 
compatible platelets as compared to incompatible platelets. Because of limitations inherent 
to the study design, no definitive statement can be made. These results demonstrate that 
larger prospective studies must be performed to inform the need for ABO matching in 
critically ill children requiring platelet transfusions. Further confirmatory studies are needed 
Nellis et al. Page 8
Pediatr Crit Care Med. Author manuscript; available in PMC 2020 February 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
that may require assessment of additional outcomes such as organ failure and clinical 
bleeding in critically ill children.
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Figure 1. 
Interval change in Total Platelet Count for each compatibility group
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Figure 2. 
Interval change in Total Platelet Count in bleeding versus non-bleeding subjects for each 
compatibility group
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Table 1.
Demographics and Clinical Characteristics of Patients
Patient Variable Compatible
(n = 342)
Major Incompatibility
( n = 133)
Minor
Incompatibility
(n = 28)
p-Values
Age (yr), median (IQR) 4.5 (0.7–11.1) 3.1 (0.4–10.3) 3.1 (0.2–10.7) 0.38
Sex (male), n (%) 183 (54) 85 (64) 13 (46) 0.07
Weight (kg), median (IQR) 16.8 (7.2–35.6) 15.7 (5.4–32.2) 13.0 (4.1–41.5) 0.37
Days since admission, median (IQR) 3 (0–7) 2 (0–7) 2 (1–6) 0.93
Mechanical ventilation, n (%) 224 (66) 84 (63) 22 (79) 0.28
Underlying oncologic diagnosis, n (%) 148 (43) 56 (42) 12 (43) 0.97
PELOD-2 Score prior to transfusion, median (IQR) 7 (4–9) 7 (5–9) 9 (6–10) 0.04
ABO blood type of recipient
 O 155 (43) 93 (70) 0 (0)
 A 127 (37) 16 (12) 14 (50)
 B 43 (13) 24 (18) 6 (21)
 AB 17 (5) 0 (0) 8 (29)
p-values comparing medians using Kruskal Wallis test and categorical variables using Chi-square test
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Table 2.
Admitting Diagnoses and Therapies Received
Admitting Diagnoses Compatible
(n = 342)
Major Incompatibility
( n = 133)
Minor
Incompatibility
(n = 28)
p-values
Reason for PICU Admission, n (%):
 Organ Failure
  Respiratory insufficiency/failure 141 (41) 53 (40) 10 (36) 0.83
  Renal failure 32 (9) 16 (12) 1 (4) 0.36
  Hepatic failure 18 (5) 7 (5) 1 (4) 0.93
 Shock
  Septic shock 88 (26) 18 (14) 7 (25) 0.02
  Hemorrhagic shock 21 (6) 7 (5) 1 (4) 0.82
  Other shock 15 (4) 6 (5) 0 (0) 0.52
 Trauma 8 (2) 5 (4) 0 (0) 0.46
 Cardiac
  Cardiac surgery-bypass 39 (11) 18 (14) 3 (11) 0.80
  Cardiac surgery-no bypass 6 (2) 4 (3) 0 (0) 0.50
  Cardiac – non-surgical 27 (8) 16 (12) 6 (21) 0.04
 Post-operative
  Emergency surgery 14 (4) 7 (5) 0 (0) 0.45
  Elective surgery 14 (4) 10 (8) 0 (0) 0.14
  Post-op liver transplant 10 (3) 2 (2) 1 (4) 0.64
 Neurosurgical
  Traumatic brain injury 5 (2) 3 (2) 0 (0) 0.65
  Intracranial bleed/intracranial hypertension 9 (3) 3 (2) 0 (0) 0.68
 Neurologic
  Seizure 9 (3) 2 (2) 2 (7) 0.23
  Encephalopathy 29 (9) 8 (6) 2 (7) 0.66
  Meningitis 4 (1) 1 (1) 0 (0) 0.72
 Veno-occlusive disease 4 (1) 2 (2) 0 (0) 0.80
 New leukemia/hyperleukocytosis 14 (4) 2 (2) 2 (7) 0.23
 Hemophagocytic lymphohistiocytosis 5 (2) 1 (1) 0 (0) 0.68
 Other 25 (7) 6 (5) 4 (14) 0.16
Therapies Received, n (%)
 Medications
  Milrinone 55 (16) 26 (20) 4 (14) 0.62
  Non-steroidal anti-inflammatories 5 (2) 5 (4) 0 (0) 0.20
  Aspirin 9 (3) 4 (3) 0 (0) 0.66
 Devices
  Extracorporeal Membrane Oxygenation 60 (18) 18 (14) 7 (25) 0.29
  Continuous renal replacement therapy 31 (9) 18 (14) 3 (11) 0.36
  Intermittent hemodialysis 3 (1) 3 (2) 0 (0) 0.54
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Admitting Diagnoses Compatible
(n = 342)
Major Incompatibility
( n = 133)
Minor
Incompatibility
(n = 28)
p-values
  Molecular adsorbent circulating system 2 (0.6) 3 (2) 0 (0) 0.26
Median (IQR) dose (mL/kg) platelet transfusions received prior to 
enrollment
30 (12–77) 58 (22–108) 19 (11–29) 0.06
p-values calculated using Chi-squared for large samples and Fisher’s Exact for small samples
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Table 3.
Distribution of ABO compatibility groups for bleeding versus non-bleeding indications
Indication Compatible
(342)
Major Incompatibility
(133)
Minor
Incompatibility
(28)
p-Values
Bleeding 110 (32) 56 (42) 6 (21) 0.04
Non-bleeding (prophylaxis) 232 (68) 77 (58) 22 (79) 0.04
p-values calculated variables using Chi-square test (or Fisher’s Exact for small samples).
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Table 4.
Attributes of Platelet Products Transfused
Transfusion Variable Compatible
(342)
Major Incompatibility
(133)
Minor
Incompatibility
(28)
p-Values
Apheresed platelets 288 (84) 128 (96) 27 (96) 0.001
Whole blood derived platelets 54 (16) 5 (4) 1 (4) 0.001
Leukoreduction 320 (94) 128 (96) 27 (100) 0.61
Irradiation 267 (78) 111 (84) 22 (79) 0.39
HLA-matched 2 (1) 0 (0) 0 (0) 0.87
Volume reduced (washed) 23 (7) 11 (8) 4 (15) 0.19
Pathogen inactivated 16 (5) 5 (4) 2 (7) 0.20
Storage duration 4 (3–5) 5 (4–5) 5 (4–5) 0.10
All variables reported as n (%) except for storage duration which is reported as median (IQR). p-values comparing medians using Kruskal Wallis 
test and categorical variables using Chi-square test (or Fisher’s Exact for small samples). There was missing data on leukoreduction in 3 cases, 
irradiation in 6 cases, HLA matching in 17 cases, volume reduction in 46 cases, pathogen inactivation in 38 cases, and storage duration in 44 cases. 
For all analyses, complete-case analysis approach was applied.
Pediatr Crit Care Med. Author manuscript; available in PMC 2020 February 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Nellis et al. Page 19
Table 5.
Transfusion Reactions
Reactions Compatible (332) Incompatible (161) p-Values
Any transfusion reaction n (%) 25 (7) 5 (3) 0.07
  New fever 9 (3) 2 (1) 0.36
  Increase in temp by 1C if already febrile 2 (0.6) 1 (0.6) 0.66
  Urticaria 2 (0.6) 1 (0.6) 0.99
  Bronchospasm 1 (0.3) 0 (0) 0.99
  Hypotension 12 (4) 1 (0.6) 0.07
 
Transfusion stopped 2 (0.6) 1 (0.6) 0.99
All variables reported as n (%). There were no hemolytic reactions reported for any of the transfusions. p-values calculated using Chi-squared for 
large samples and Fisher’s Exact for small samples.
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